Literature DB >> 20616681

Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration.

Karen Bjerg Pedersen1, Flemming Møller, Anne Katrin Sjølie, Sten Andréasson.   

Abstract

PURPOSE: The purpose of this study was to assess the alteration of retinal function by multifocal electroretinography and full-field electroretinography in patients with age-related macular degeneration treated with bevacizumab.
METHODS: We performed a prospective pilot study of 26 eyes of 26 previously treatment-naïve patients with neovascular age-related macular degeneration receiving intravitreal injections with 1.25 mg bevacizumab. Patients were examined with multifocal electroretinography, full-field electroretinography, optical coherence tomography, and visual acuity. Follow-up was performed at 1 week, 6 weeks, 3 months, and 6 months.
RESULTS: Mean multifocal electroretinography P1 amplitudes were significantly improved at 1 week in the central zone and after 3 and 6 months, improvement was seen in all 6 concentric rings corresponding to +/-25 degrees of the central visual field. Full-field electroretinography results indicated a decrease in cone photoreceptor function at 3 months, which was normalized at 6 months compared with baseline. Furthermore, 2 of 3 of the combined rod-cone responses showed signs of decreased retinal function at 6 months.
CONCLUSION: Our results indicate passing signs of an altered retinal cone photoreceptor function assessed by full-field electroretinography. The results do not show any conclusive signs of global retinal toxicity after 6 months. Multifocal electroretinography results show improved photoreceptor function with no sign of focal toxicity in the central retina.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616681     DOI: 10.1097/IAE.0b013e3181cafc8f

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  13 in total

1.  Test-retest repeatability of the pattern electroretinogram and flicker electroretinogram.

Authors:  Arthur F Resende; Carina T Sanvicente; Hamoon Eshraghi; Alberto Garcia; Kassandra Pickel; Qiang Zhang; Michael Waisbourd; L Jay Katz
Journal:  Doc Ophthalmol       Date:  2019-07-16       Impact factor: 2.379

2.  Structural and functional assessment after intravitreal injection of ranibizumab in diabetic macular edema.

Authors:  YuDong Fu; Ping Wang; XuXia Meng; Zhaodong Du; DaBo Wang
Journal:  Doc Ophthalmol       Date:  2017-07-29       Impact factor: 2.379

3.  Extrafoveal changes following intravitreal bevacizumab injections for macular edema secondary to branch retinal vein occlusion: an mfERG and OCT study.

Authors:  Saemi Park; In Hwan Cho; Tae Kwann Park; Woo Ho Nam; Young-Hoon Ohn
Journal:  Doc Ophthalmol       Date:  2012-12-20       Impact factor: 2.379

4.  Clinical, anatomical, and electrophysiological assessments of the central retina following intravitreal bevacizumab for macular edema secondary to retinal vein occlusion.

Authors:  Eleni Loukianou; Dimitrios Brouzas; Klio Chatzistefanou; Chrysanthi Koutsandrea
Journal:  Int Ophthalmol       Date:  2015-03-29       Impact factor: 2.031

5.  Fixation stability and implication for multifocal electroretinography in patients with neovascular age-related macular degeneration after anti-VEGF treatment.

Authors:  K B Pedersen; A K Sjølie; A H Vestergaard; S Andréasson; F Møller
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-14       Impact factor: 3.117

6.  Peripheral retinal function assessed with 30-Hz flicker seems to improve after treatment with Lucentis in patients with diabetic macular oedema.

Authors:  Kristina Holm; Marion Schroeder; Monica Lövestam Adrian
Journal:  Doc Ophthalmol       Date:  2015-03-15       Impact factor: 2.379

7.  Evaluation of structural and functional changes in non-pathologic myopic fundus using multifocal electroretinogram and optical coherence tomography.

Authors:  Saemi Park; Seung Hoon Kim; Tae Kwann Park; Young-Hoon Ohn
Journal:  Doc Ophthalmol       Date:  2013-03-08       Impact factor: 2.379

8.  The effect of intravitreal bevacizumab (Avastin) on ocular pulse amplitude in neovascular age-related macular degeneration.

Authors:  Ehud Rechtman; Ingeborg Stalmans; Joseph Glovinsky; Christophe Breusegem; Joseph Moisseiev; Joachim Van Calster; Alon Harris
Journal:  Clin Ophthalmol       Date:  2011-01-06

Review 9.  Quantitative physiological measurements to evaluate the response of antivascular endothelial growth factor treatment in patients with neovascular diseases.

Authors:  In Hwan Hong; Sung Pyo Park
Journal:  Indian J Ophthalmol       Date:  2017-07       Impact factor: 1.848

10.  Testing the clinical value of multifocal electroretinography and microperimetry and the effects of intravitreal therapy with ranibizumab on macular function in the course of wet age-related macular degeneration: a 1-year prospective study.

Authors:  Mihaela Reinsberg; Ralf-Dieter Hilgers; Inger Lüdeke; Khaled Nassar; Swaantje Grisanti; Salvatore Grisanti; Julia Lüke; Matthias Lüke
Journal:  Clin Ophthalmol       Date:  2017-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.